Results 251 to 260 of about 7,661,292 (297)
Some of the next articles are maybe not open access.
Growth and Growth Hormone Therapy in Hypochondroplasia
Acta Paediatrica, 1990ABSTRACT. The growth of 84 patients with hypochondroplasia (56 male, 28 female) was studied. A wide spectrum of severity was found from quite severe short limbed dwarfism to short apparently normal prepubertal children who manifested disproportion only at puberty when growth failed.
S, Appan +4 more
openaire +2 more sources
Growth Hormone Therapy in Achondroplasia
Hormone Research in Paediatrics, 2000Achondroplasia is one of the most common causes of severe rhizomelic dwarfism. We have previously reported the growth-promoting effect of growth hormone (GH) in this disorder. In this expanded clinical study, dose dependency and the long-term effect of GH were also investigated.
Y, Seino +8 more
openaire +2 more sources
Best Practice & Research Clinical Endocrinology & Metabolism, 2002
Since 1958 growth hormone (GH) has been used as substitution treatment for children with GH deficiency. At present, it is clear that a dose of 0.23 mg/kg/week can lead to a final height close to target height, but in view of the wide inter-individual variation, alternative regimens based on invidualizing the dosage with the help of prediction models ...
openaire +3 more sources
Since 1958 growth hormone (GH) has been used as substitution treatment for children with GH deficiency. At present, it is clear that a dose of 0.23 mg/kg/week can lead to a final height close to target height, but in view of the wide inter-individual variation, alternative regimens based on invidualizing the dosage with the help of prediction models ...
openaire +3 more sources
Growth hormone therapy in achondroplasia
American Journal of Medical Genetics, 1992AbstractA pilot study was carried out to examine the safety and efficacy of recombinant human growth hormone for growth‐promoting therapy of achondroplasia. The data suggest that the agent in doses used to treat non‐GH‐deficient forms of short stature (0.3 mg/kg/wk) modestly increases overall height velocity in some children with achondroplasia.
W A, Horton +5 more
openaire +2 more sources
Growth Hormone Therapy in Progeria
Journal of Pediatric Endocrinology and Metabolism, 2007Catabolic processes seen in Hutchinson-Gilford progeria resemble those of normal aging and, in the affected children, usually result in death at an early age. In addition to its growth promoting effects, growth hormone (GH) has potent anabolic properties. Administration of GH ameliorates some of the catabolic effects of normal aging.
Ab, Sadeghi-Nejad, Laurie, Demmer
openaire +2 more sources
Growth Hormone Therapy and Malignancy
Hormone Research, 2009The possibility that human growth hormone (GH) replacement therapy might either increase the risk of cancer recurrence in a child who has previously been treated for a brain tumour or leukaemia, or induce de novo cancer, has worried paediatricians for a number of years.
S M, Shalet +2 more
openaire +2 more sources
Growth hormone therapy in achondroplasia
Acta Endocrinologica, 1993The status of growth hormone (GH) secretion together with the effect of GH therapy was studied in six children with achondroplasia. One patient had impaired GH secretion, which may, in part, be due to obesity. The pre-GH-treatment height velocity was 3.8±0.7 cm/year, but this increased to 6.0±1.0 cm/year in the first year of treatment and to 4.4±0.6 cm/
Y, Nishi +4 more
openaire +2 more sources
Growth hormone therapy and leukaemia
European Journal of Pediatrics, 1989Following an initial report from Japan in 1987, 15 growth hormone (GH)-deficient patients developed leukaemia during or following GH treatment. Nearly all available pituitary and biosynthetic growth hormones have been used. In 14 of these 15 patients GH treatment was initiated in 1975 or later with doses between 4.5 and 18IU/m2 per week.
N, Stahnke, H J, Zeisel
openaire +2 more sources
Growth hormone therapy in hypochondroplasia
Acta Paediatrica, 1999Ramaswami U, Hindmarsh PC, Brook CGD. Growth hormone therapy in hypochondroplasia. Acta Pædiatr 1999; Suppl 428: 116–17. Stockholm. ISSN 0803–5326Patients with hypochondroplasia present with variable phenotypes. Children with severe short stature and disproportion of the body segments usually have the mutation Asn540Lys. They respond to growth hormone (
U, Ramaswami, P C, Hindmarsh, C G, Brook
openaire +2 more sources
Growth Hormone Therapy and the Heart
The American Journal of Cardiology, 2006The growth hormone (GH)-insulin-like growth factor-1 axis has great relevance for the regulation of cardiac growth, structure, and function. GH deficiency may result in impaired cardiac performance, manifest by a reduction in left ventricular mass and ejection fraction, but data are inconsistent.
Vicente E, Climent +5 more
openaire +2 more sources